Related Experiment Video
Updated: Dec 21, 2025

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Teriflunomide Does Not Change Dynamics of Nadph Oxidase Activation and Neuronal Dysfunction During Neuroinflammation
Ronja Mothes1,2, Carolin Ulbricht2,3, Ruth Leben2
1Institute for Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Abstract:
The multiple sclerosis therapeutic teriflunomide is known to block the de novo synthesis of pyrimidine in mitochondria by inhibiting the enzyme dihydroorotate-dehydrogenase (DHODH). The metabolic processes of oxidative phosphorylation and glycolysis are further possible downstream targets. In healthy adult mice, high levels of dihydroorotate-dehydrogenase (DHODH) activity are measured in the central nervous system (CNS), and DHODH inhibition may cause indirect effects on reactive oxygen species production and NADPH oxidase (NOX) mediated oxidative stress, known to be key aspects of the inflammatory response of the CNS. However, little is known about the effect of teriflunomide on the dynamics of NOX activation in CNS cells and subsequent alterations of neuronal function in vivo. In this study, we employed fluorescence lifetime imaging (FLIM) and phasor analysis of the endogeneous fluorescence of NAD(P)H (nicotinamide adenine dinucleotide phosphate) in the brain stem of mice to visualize the effect of teriflunomide on cellular metabolism. Furthermore, we simultaneously studied neuronal Ca2+ signals in transgenic mice with a FRET-based Troponin C Ca2+ sensor based (CerTN L15) quantified using FRET-FLIM. Hence, we directly correlated neuronal (dys-)function indicated by steadily elevated calcium levels with metabolic activity in neurons and surrounding CNS tissue. Employing our intravital co-registered imaging approach, we could not detect any significant alteration of NOX activation after incubation of the tissue with teriflunomide. Furthermore, we could not detect any changes of the inflammatory induced neuronal dysfunction due to local treatment with teriflunomide. Concerning drug safety, we can confirm that teriflunomide has no metabolic effects on neuronal function in the CNS tissue during neuroinflammation at concentrations expected in orally treated patients. The combined endogenous FLIM and calcium imaging approach developed by us and employed here uniquely meets the need to monitor cellular metabolism as a basic mechanism of tissue functions in vivo.
Insights
Teriflunomide, a multiple sclerosis drug, does not affect NADPH oxidase (NOX) activation or cause metabolic changes in central nervous system (CNS) cells during neuroinflammation, confirming its safety for neuronal function.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Teriflunomide inhibits dihydroorotate-dehydrogenase (DHODH), impacting pyrimidine synthesis and potentially oxidative phosphorylation and glycolysis.
- DHODH activity is high in the CNS, and its inhibition may affect oxidative stress and NADPH oxidase (NOX) activation, key in CNS inflammation.
- The effects of teriflunomide on NOX activation dynamics and neuronal function in vivo remain largely unknown.
Purpose of the Study:
- To investigate the impact of teriflunomide on NOX activation and neuronal function in the mouse CNS during neuroinflammation.
- To correlate cellular metabolism with neuronal function using advanced imaging techniques.
- To assess the safety of teriflunomide regarding metabolic effects on CNS tissue.
Main Methods:
- Utilized fluorescence lifetime imaging (FLIM) and phasor analysis of endogenous NAD(P)H fluorescence to monitor cellular metabolism in mouse brain stems.
- Simultaneously measured neuronal calcium (Ca2+) signals using FRET-FLIM in transgenic mice.
- Employed intravital co-registered imaging to directly correlate metabolic activity with neuronal function.
Main Results:
- No significant alterations in NOX activation were detected after teriflunomide treatment.
- Teriflunomide did not change inflammatory-induced neuronal dysfunction.
- Confirmed that teriflunomide has no adverse metabolic effects on CNS neuronal function at expected therapeutic concentrations.
Conclusions:
- Teriflunomide does not appear to activate NOX or negatively impact neuronal function or metabolism in the CNS during neuroinflammation.
- The study validates the safety of teriflunomide for neuronal function in the CNS at therapeutic doses.
- The developed FLIM and calcium imaging approach offers a novel method for in vivo monitoring of cellular metabolism and neuronal function.
More Related Videos
12:48In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
Published on: May 11, 2015
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Drugs Affecting Neurotransmitter Release or Uptake